Septerna, IPO
Septerna Shares Set for Trading Debut After Upsized IPO
Shares of Septerna are set to maker their trading debut Friday after the clinical-stage biotechnology's upsized initial public offering. The South San Francisco company late Thursday said it is selling 16 million shares at $18 apiece in the IPO, up from prior plans to offer about 15.3 million shares.
Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...
Septerna is the 23rd biotech to go public this year, raising funds to advance its lead candidate, a treatment for ...
Septerna is seeking a valuation of $743.1 million in its upsized U.S. initial public offering, the Goldman Sachs-backed drug ...
Septerna stock has risen 29%, to $23.31, since it debuted on the exchange Friday. The San Francisco biotechnology company said Thursday it would sell 16 million shares at $18 apiece, giving the ...
Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor ...
Recent developments in healthcare cover a broad spectrum of issues: an analysis reveals that weight-loss drugs like Wegovy do ...
Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on ...
Goldman Sachs-backed Septerna would be valued around $750 million. Drug developers have achieved resounding success in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback